Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products that can be applied topically to treat diseases of the skin. The company has built a proprietary platform that includes a microbial library comprised of bacterial strains that can be screened for therapeutic characteristics. The platform is augmented by artificial intelligence and machine learning technology that analyzes, predicts and helps screen the library of strains for drug-like molecules. The platform also utilizes a licensed genetic engineering technology, which can enable the transformation of previously genetically intractable strains.

Azitra, Inc.

Azitra develops novel therapeutics to treat adverse skin conditions and disease using microbial and genetic engineering approaches for precision dermatology.

Azitra

Azitra, Inc. is a preclinical stage biotechnology company harnessing the power of the microbiome to treat skin disease. The Company was founded in 2014 by scientists from Yale University and works with world-leading scientists in dermatology, microbiology, and genetic engineering to advance its programs in atopic dermatitis and targeted orphan indications. For more information visit www.azitrainc.com.

National Institutes of Health

National Science Foundation

U.S. Department of Defense

Bios Partners

Connecticut Innovations

Godfrey Capital

KdT Ventures

Leaps by Bayer

Sahsen Ventures

Azitra Inc

Azitra Announces First Patient Screened and Scheduled to Enroll in Phase 1b Trial of ATR-12 for Netherton Syndrome

https://lnkd.in/eb2fzkQd

Azitra Inc (NYSE American: AZTR) Announces Pricing of $10.0 Million Public Offering. Maxim Group LLC is acting as the exclusive placement agent.

Read the full press release: https://lnkd.in/eiM4dhwu

Brad Hoffman, Danny Fossey, Robert Solomon, Stephen Polsinelli

Today, we're announcing the strengthening of our IP portfolio with a newly issued US patent and three additional patent allowances globally. 

Read more here:

https://lnkd.in/eNAB7rMF

We'll be at the Foundation for Foundation for Ichthyosis & Related Skin Types, Inc. (FIRST) conference this weekend to connect with patients and share about our clinical trial for Netherton syndrome at Azitra.

#FIRSTNC24 #NethertonSyndrome

We'll be at the Society of Investigative Dermatology this Friday in Dallas presenting new data on our platform and ATR-04

This Friday, we'll be presenting new data on our platform and Netherton syndrome program at ASGCT 2024. Stop by if you'll be there! 

https://lnkd.in/e_j2riaH

Today, we’re announcing the issuance of a new patent to strengthen our IP position and bolster our platform for precision dermatology.

https://lnkd.in/eMWwZqVn

	Dec '21	Dec '22	Dec '23
account payables	717.80K -	784.69K 9.32%	897.27K 14.35%
accumulated other comprehensive income loss			-5.12M -
cash and cash equivalents	8.04M -	3.49M 56.58%	1.80M 48.58%
cash and short term investments	8.04M -	3.49M 56.58%	1.80M 48.58%
common stock	1.47K -	1.47K 0.07%	1.21K 17.69%
deferred revenue	15K -	156K 940%
deferred revenue non current
deferrred tax liabilities non current
goodwill
goodwill and intangible assets	97.69K -	219.57K 124.75%	210.88K 3.96%
intangible assets	97.69K -	219.57K 124.75%	210.88K 3.96%
inventory			-215.22K -
long term debt	992.02K -	7.44M 650.08%	563.69K 92.42%
long term investments
net debt	-7.05M -	4.24M 160.06%	-910.04K 121.49%
net receivables	334.18K -	266.21K 20.34%	223.47K 16.05%
other assets
other current assets			731.34K -
other current liabilities	476.79K -	1.99M 316.94%	383.67K 80.70%
other liabilities
other non current assets	668.23K -	848.34K 26.95%	789.99K 6.88%
other non current liabilities	33.77M -	33.76M 0.00%	35.45K 99.90%
othertotal stockholders equity	866.80K -	1.05M 21.46%	51.51M 4,792.82%
preferred stock			5.12M -
property plant equipment net	946.68K -	1.96M 107.43%	1.58M 19.59%
retained earnings	-26.63M -	-37.31M 40.10%	-48.60M 30.24%
short term debt		287.38K -	322.25K 12.13%
short term investments
tax assets
tax payables	1.30K -
total assets	10.20M -	7.17M 29.74%	5.12M 28.63%
total current assets	8.49M -	4.14M 51.28%	2.54M 38.69%
total current liabilities	1.21M -	2.22M 83.70%	1.60M 27.85%
total debt	992.02K -	7.73M 679.05%	885.95K 88.54%
total investments
total liabilities	35.97M -	43.43M 20.74%	2.20M 94.93%
total liabilities and stockholders equity	10.20M -	7.17M 29.74%	5.12M 28.63%
total non current assets	1.71M -	3.03M 77.01%	2.58M 14.90%
total non current liabilities	34.76M -	41.21M 18.55%	599.14K 98.55%
total stockholders equity	-25.77M -	-36.26M 40.73%	2.91M 108.03%

AZTR

COM:AZITRAINC

Azitra

Last Close

0.47

21/11 21:00

Market Cap

3.58M

Beta: -

Volume Today

121.25K

Avg: -

Preview